BlackSky Technology 株価情報 (NYSE: BKSY)

最新ニュース BlackSky Technology (NYSE:BKSY) 株価情報

BLACKSKY TECHNOLOGY INC

BlackSky Technology

BlackSky Technology Inc is a provider of real-time geospatial intelligence. The company delivers on-demand, high-frequency imagery, monitoring, and analytics of some of the critical and strategic locations, economic assets, and events in the world. It designs, owns, and operates one of the industry's low earth orbit (LEO) small satellite constellations, optimized to capture imagery cost-efficiently where and when its customers need it. its Spectra AI software platform processes data from BlackSky's constellation and other third-party sensors to develop the critical insights and analytics that provide its customers with the actionable intelligence. Geographically, the company operates in North America, the Middle East, Asia, and Others.

BlackSky Technology Inc. Class A Common Stock

BlackSky Technology Inc

BlackSky Technology Inc. Redeemable Warrants, each whole Warrant exercisable for one share of Class A Common Stock

Blink Charging (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLNK#NASDAQ">BLNK</a>) reported quarterly losses of $(0.18) per share which missed the analyst consensus estimate of $(0.14) by 28.57 percent. This is a 38.46 percent decrease over losses of $(0.13) per share from the same period last year. The company reported quarterly sales of $20.75 million which missed the analyst consensus estimate of $27.60 million by 24.81 percent. This is a 44.76 percent decrease over sales of $37.57 million the same period last year.

Earnings

Earnings Misses

News

BLNK

Blink Charging Q1 Adj. EPS $(0.18) Misses $(0.14) Estimate, Sales $20.75M Miss $27.60M Estimate

Hudson Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSON#NASDAQ">HSON</a>) is set to give its latest quarterly earnings report on Tuesday, 2025-05-13. Here's what investors need to know before the announcement.
Analysts estimate that Hudson Global will report an earnings per share (EPS) of $0.06. 
The announcement from Hudson Global is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Historical Earnings Performance</h3>
Last quarter the company beat EPS by $0.11, which was followed by a 0.0% drop in the share price the next day.
Here's a look at Hudson Global's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.16</td>
<td>0</td>
<td>-0.07</td>
<td>0.05</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.05</td>
<td>-0.13</td>
<td>0.04</td>
<td>-0.72</td>
</tr>
<tr>
<td>Price Change %</td>
<td>3.0%</td>
<td>-1.0%</td>
<td>1.0%</td>
<td>2.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1747080515_0.png" alt="eps graph" />
<h3>Performance of Hudson Global Shares</h3>
Shares of Hudson Global were trading at $10.1999 as of May 09. Over the last 52-week period, shares are down 38.34%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/HSON/earnings">To track all earnings releases for Hudson Global visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

HSON

Hudson Global's Earnings: A Preview

UBS analyst Timothy Arcuri maintains Analog Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADI#NASDAQ">ADI</a>) with a Buy and lowers the price target from $300 to $295.

Price Target

Analyst Ratings

UBS Maintains Buy on Analog Devices, Lowers Price Target to $295

OptimizeRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) reported quarterly earnings of $0.08 per share which beat the analyst consensus estimate of $(0.12) by 166.67 percent. This is a 172.73 percent increase over losses of $(0.11) per share from the same period last year. The company reported quarterly sales of $21.93 million which beat the analyst consensus estimate of $18.69 million by 17.35 percent. This is a 11.37 percent increase over sales of $19.69 million the same period last year.

Earnings Beats

OPRX

OptimizeRx Q1 Adj. EPS $0.08 Beats $(0.12) Estimate, Sales $21.93M Beat $18.69M Estimate

Archer Aviation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NYSE">ACHR</a>) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.28) by 39.29 percent. This is a 52.78 percent increase over losses of $(0.36) per share from the same period last year.

ACHR

Archer Aviation Q1 EPS $(0.17) Beats $(0.28) Estimate

Maravai LifeSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVI#NASDAQ">MRVI</a>) reported quarterly losses of $(0.08) per share which missed the analyst consensus estimate of $(0.07) by 14.29 percent. This is a 300 percent decrease over losses of $(0.02) per share from the same period last year. The company reported quarterly sales of $46.85 million which beat the analyst consensus estimate of $44.01 million by 6.46 percent. This is a 27.00 percent decrease over sales of $64.18 million the same period last year.

MRVI

Maravai LifeSciences Q1 Adj. EPS $(0.08) Misses $(0.07) Estimate, Sales $46.85M Beat $44.01M Estimate

ACCESS Newswire (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ACCS#AMEX">ACCS</a>) is set to give its latest quarterly earnings report on Tuesday, 2025-05-13. Here's what investors need to know before the announcement.
Analysts estimate that ACCESS Newswire will report an earnings per share (EPS) of $0.13. 
Investors in ACCESS Newswire are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Past Earnings Performance</h3>
During the last quarter, the company reported an EPS missed by $0.02, leading to a 3.14% drop in the share price on the subsequent day.
Here's a look at ACCESS Newswire's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.23</td>
<td>0.20</td>
<td>0.21</td>
<td>0.29</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.21</td>
<td>0.17</td>
<td>0.22</td>
<td>0.08</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-3.0%</td>
<td>-5.0%</td>
<td>3.0%</td>
<td>-17.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1747080473_0.png" alt="eps graph" />
<h3>Tracking ACCESS Newswire's Stock Performance</h3>
Shares of ACCESS Newswire were trading at $8.9 as of May 09. Over the last 52-week period, shares are down 10.71%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/ACCS/earnings">To track all earnings releases for ACCESS Newswire visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACCS

Preview: ACCESS Newswire's Earnings

Simon Property Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPG#NYSE">SPG</a>) affirms FY2025 FFO guidance from $12.40-$12.65 to $12.40-$12.65 vs $12.56 analyst estimate..

Guidance

Simon Property Group Affirms FY2025 FFO Guidance of $12.40-$12.65 vs $12.56 Est

Rigetti Computing (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>) reported quarterly earnings of $0.13 per share which beat the analyst consensus estimate of $(0.06) by 316.67 percent. This is a 192.86 percent increase over losses of $(0.14) per share from the same period last year. The company reported quarterly sales of $1.47 million which missed the analyst consensus estimate of $2.55 million by 42.29 percent. This is a 51.77 percent decrease over sales of $3.05 million the same period last year.

RGTI

Rigetti Computing Q1 EPS $0.13 Beats $(0.06) Estimate, Sales $1.47M Miss $2.55M Estimate

Achieve Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHV#NASDAQ">ACHV</a>) is gearing up to announce its quarterly earnings on Tuesday, 2025-05-13. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Achieve Life Sciences will report an earnings per share (EPS) of $-0.36.
The market awaits Achieve Life Sciences's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Past Earnings Performance</h3>
Last quarter the company missed EPS by $0.00, which was followed by a 9.25% drop in the share price the next day.
Here's a look at Achieve Life Sciences's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.36</td>
<td>-0.26</td>
<td>-0.23</td>
<td>-0.23</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.36</td>
<td>-0.36</td>
<td>-0.25</td>
<td>-0.26</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-9.0%</td>
<td>-7.000000000000001%</td>
<td>1.0%</td>
<td>2.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1747080462_0.png" alt="eps graph" />
<h3>Achieve Life Sciences Share Price Analysis</h3>
Shares of Achieve Life Sciences were trading at $2.35 as of May 09. Over the last 52-week period, shares are down 50.6%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/ACHV/earnings">To track all earnings releases for Achieve Life Sciences visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACHV

What to Expect from Achieve Life Sciences's Earnings

FRP Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRPH#NASDAQ">FRPH</a>) reported quarterly earnings of $0.09 per share. This is a 28.57 percent increase over earnings of $0.07 per share from the same period last year. The company reported $10.31 million in sales this quarter. This is a 1.71 percent increase over sales of $10.13 million the same period last year.

FRPH

FRP Holdings Q1 EPS $0.09 Up From $0.07 YoY, Sales $10.31M Up From $10.13M YoY

Dare Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DARE#NASDAQ">DARE</a>) is preparing to release its quarterly earnings on Tuesday, 2025-05-13. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Dare Bioscience to report an earnings per share (EPS) of $-0.58.
Anticipation surrounds Dare Bioscience's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Performance in Previous Earnings</h3>
Last quarter the company missed EPS by $0.02, which was followed by a 0.35% increase in the share price the next day.
Here's a look at Dare Bioscience's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.63</td>
<td>-0.71</td>
<td></td>
<td>-0.72</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.65</td>
<td>-0.55</td>
<td>1.52</td>
<td>-0.84</td>
</tr>
<tr>
<td>Price Change %</td>
<td>0.0%</td>
<td>-10.0%</td>
<td>20.0%</td>
<td>14.000000000000002%</td>
</tr>
</tbody>
</table>

<h3>Performance of Dare Bioscience Shares</h3>
Shares of Dare Bioscience were trading at $2.91 as of May 09. Over the last 52-week period, shares are down 23.76%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/DARE/earnings">To track all earnings releases for Dare Bioscience visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

DARE

Dare Bioscience's Earnings Outlook

Xtant Medical Hldgs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/XTNT#AMEX">XTNT</a>) raises FY2025 sales outlook from $126.00 million-$130.00 million to $127.00 million-$131.00 million vs $128.35 million estimate.

XTNT

Xtant Medical Hldgs Raises FY2025 Sales Guidance from $126.00M-$130.00M to $127.00M-$131.00M vs $128.35M Est

Rapid7 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPD#NASDAQ">RPD</a>) reported quarterly earnings of $0.49 per share which beat the analyst consensus estimate of $0.35 by 40 percent. This is a 10.91 percent decrease over earnings of $0.55 per share from the same period last year. The company reported quarterly sales of $210.25 million which beat the analyst consensus estimate of $208.23 million by 0.97 percent. This is a 2.51 percent increase over sales of $205.10 million the same period last year.

Rapid7 Q1 Adj. EPS $0.49 Beats $0.35 Estimate, Sales $210.25M Beat $208.23M Estimate

Karyopharm Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KPTI#NASDAQ">KPTI</a>) reported quarterly losses of $(2.77) per share which beat the analyst consensus estimate of $(4.16) by 33.41 percent. This is a 42.89 percent increase over losses of $(4.85) per share from the same period last year. The company reported quarterly sales of $30.02 million which missed the analyst consensus estimate of $35.24 million by 14.83 percent. This is a 9.39 percent decrease over sales of $33.13 million the same period last year.

KPTI

Karyopharm Therapeutics Q1 EPS $(2.77) Beats $(4.16) Estimate, Sales $30.02M Miss $35.24M Estimate

ZoomInfo Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZI#NASDAQ">ZI</a>) reported quarterly earnings of $0.23 per share which beat the analyst consensus estimate of $0.22 by 4.55 percent. This is a 11.54 percent decrease over earnings of $0.26 per share from the same period last year. The company reported quarterly sales of $305.70 million which beat the analyst consensus estimate of $295.30 million by 3.52 percent. This is a 1.42 percent decrease over sales of $310.10 million the same period last year.

ZoomInfo Technologies Q1 Adj. EPS $0.23 Beats $0.22 Estimate, Sales $305.70M Beat $295.30M Estimate

Simon Property Group Q1 FFO, Sales $1.47B Beat $1.36B Estimate

Repay Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPAY#NASDAQ">RPAY</a>) reported quarterly earnings of $0.22 per share which met the analyst consensus estimate. This is a 4.35 percent decrease over earnings of $0.23 per share from the same period last year. The company reported quarterly sales of $77.33 million which beat the analyst consensus estimate of $75.72 million by 2.11 percent. This is a 4.21 percent decrease over sales of $80.72 million the same period last year.

RPAY

Repay Hldgs Q1 Adj. EPS $0.22, Inline, Sales $77.33M Beat $75.72M Estimate

Xtant Medical Hldgs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/XTNT#AMEX">XTNT</a>) reported quarterly sales of $32.90 million which beat the analyst consensus estimate of $31.20 million by 5.46 percent. This is a 18.05 percent increase over sales of $27.87 million the same period last year.

Xtant Medical Hldgs Q1 Sales $32.90M Beat $31.20M Estimate

Guardian Pharmacy Service (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRDN#NYSE">GRDN</a>) affirms FY2025 sales outlook from $1.33 billion-$1.35 billion to $1.33 billion-$1.35 billion vs $1.34 billion estimate.

Comments

BlackSky Technology

ニュース

最新ニュース BlackSky Technology (NYSE:BKSY) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル